SIRENAS MARINE DISCOVERY, LLC — Department of Health and Human Services SBIR Phase I: DESCRIPTION: Though highly effective in changing the course of the global HIV epidemic, cu
SIRENAS MARINE DISCOVERY, LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $291,941
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA10-123
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION: Though highly effective in changing the course of the global HIV epidemic, current Antiretroviral Therapy (ART) fails to eradicate the infection completely. This has led to the emergence of drug-resistant mutant strains, the phenomenon of latent disease and a number of adherence and toxicity issues associate with long-term therapy. Novel compounds that inhibit transcription from integrated viral genomes, thereby preventing the production of vira particles from stable viral reservoirs, present avaluable and differentiated therapeutic potential in the treatment of HIV. Tat, a potent transactivator of HIV gene expression essential for the synthesis of full-length transcripts of the integrated viral genome by RNA polymerase II, is a highly soughtafter transcription target for the treatment of HIV. Innovation: Didehydro-cortistati A (dCA), a representative of the cortistatin class of compounds, has demonstrated significant potential as a potent inhibitor of Tat. Preliminary Data: dCA has been